Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Pfizer will seek regulatory approval for its Lyme disease vaccine candidate despite a failed late-stage trial; the failure was driven by too few Lyme infections to provide statistical confidence, though the company cited 'strong efficacy' signals. Pfizer's decision to advance a filing based on underpowered but promising efficacy data is a mixed outcome that could create near-term stock volatility and leave ultimate commercial prospects dependent on regulator judgment and labeling.

Analysis

Pfizer will seek regulatory approval for its Lyme disease vaccine candidate despite a failed late-stage trial; the failure was driven by too few Lyme infections to provide statistical confidence, though the company cited 'strong efficacy' signals. Pfizer's decision to advance a filing based on underpowered but promising efficacy data is a mixed outcome that could create near-term stock volatility and leave ultimate commercial prospects dependent on regulator judgment and labeling.